NEW YORK, October 7, 2016 /PRNewswire/ --
Stock-Callers.com today has redirected its attention to the Biotech segment which encompasses a broad scope of life-science applications such as gene editing, drug delivery systems, and the development of vaccines and biologic-based medications through cellular or biomolecular processes. This morning, equities under evaluation are: Tesaro Inc. (NASDAQ: TSRO), CTI BioPharma Corp. (NASDAQ: CTIC), Sage Therapeutics Inc. (NASDAQ: SAGE), and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX). Download the free research reports on these stocks today:
Waltham, Massachusetts headquartered Tesaro Inc.'s shares dropped 2.39%, closing Thursday's trading session at $99.89. The stock recorded a trading volume of 1.06 million shares, which was above its three months average volume of 1.04 million shares. Shares of the Company have advanced 13.28% in the last month, 12.62% over the previous three months, and 90.92% on an YTD basis. The stock is trading 4.62% above its 50-day moving average and 66.64% above its 200-day moving average. Additionally, shares of Tesaro, which identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the US and internationally, have a Relative Strength Index (RSI) of 50.07.
On September 29th, 2016, TESARO and Zai Lab (Shanghai) Co., Ltd., announced a collaboration to support the development and commercialization of niraparib for patients in China and the potential to advance two immuno-oncology programs outside of China. Within this collaboration, TESARO has granted to Zai Lab an exclusive license for the development of niraparib specifically for the China market, which includes an option for TESARO to participate in the commercialization of niraparib in greater China. See our free and comprehensive research report on TSRO at:
On Thursday, shares in Seattle, Washington headquartered CTI BioPharma Corp. recorded a trading volume of 159,493 shares. The stock fell 0.33%, ending the day at $0.40. The Company's shares have advanced 0.71% in the last month and 13.02% in the previous three months. The stock is trading above its 50-day moving average by 7.61%. Furthermore, shares of CTI BioPharma, which engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the US and internationally, have an RSI of 59.19.
On October 03rd, 2016, CTI BioPharma announced that James A. Bianco, M.D, its President and Chief Executive Officer, has retired from the Company effective on October 2nd, 2016. At the request of the Board of Directors, Richard Love, a director of CTI BioPharma since 2007, has been appointed to serve as interim President and Chief Executive Officer. CTIC free research report PDF is just a click away at:
Cambridge, Massachusetts headquartered Sage Therapeutics Inc.'s stock finished the day 5.14% lower at $43.54, and with a total trading volume of 427,224 shares. The Company's shares have gained 5.32% in the last one month and 28.17% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 5.08% and 16.17%, respectively. Additionally, shares of Sage Therapeutics, which develops and commercializes novel medicines to treat central nervous system disorders, have an RSI of 50.51.
On September 27th, 2016, Sage Therapeutics announced positive results on secondary endpoints from its Phase 2 clinical trial of SAGE-547 for the treatment of severe postpartum depression (PPD). Secondary endpoints in the study, including the Edinburgh Perinatal Depression Scale (EPDS) and the Patient Health Questionnaire (PHQ-9) showed improvement through 30 days in the SAGE-547-treated group compared to the placebo group. The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to SAGE-547 for the treatment of postpartum depression.
On October 04th, 2016, research firm Leerink Partners resumed its 'Outperform' rating on the Company's stock, issuing a target price of $68 per share. Sign up for your complimentary report on SAGE at:
Shares in The Woodlands, Texas headquartered Lexicon Pharmaceuticals Inc. ended yesterday's session 0.38% higher at $18.50. The stock recorded a trading volume of 534,334 shares. The Company's shares have advanced 24.16% in the last one month, 23.09% in the previous three months, and 38.99% on an YTD basis. The stock is trading 11.53% above its 50-day moving average and 37.07% above its 200-day moving average. Moreover, shares of Lexicon Pharmaceuticals, which focuses on the discovery and development of pharmaceutical products for the treatment of human diseases, have an RSI of 60.78.
On October 05th, 2016, Lexicon Pharmaceuticals announced that it has entered into an agreement to buy out its remaining obligations under its clinical development financing arrangement with Symphony Icon Holdings LLC upon regulatory approval in the US for the marketing and sale of telotristat ethyl. Under the buyout arrangement, Lexicon will make a single payment to Symphony Icon of $21.013 million upon US regulatory approval of telotristat ethyl. Register for free on Stock-Callers.com and download the latest research report on LXRX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA